AbbVie, Bristol-Myers get FDA nod for hep C treatments
(Reuters) - The U.S. Food and Drug Administration on Friday approved two treatments for less common forms of hepatitis C virus (HCV) infections. The regulator cleared AbbVie Inc's Technivie, which targets HCV genotype 4 infections, and Bristol-Myers Squibb Co's Daklinza, used to treat HCV genotype 3 ..
- 0 Reads
Research on Web